Multiple Tumor Types NRG-GY022

Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin

This trial studies how well iohexol works in helping doctors calculate the dose of carboplatin given to patients with cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future..

Eligibility Criteria:

  • Any patients who will receive treatment with intravenous carboplatin (any AUC, any cycle) on an NCI-sponsored NCTN-, ETCTN-, trial, local trial, or through standard of care.
  • No History of allergic reactions to CT contrast, iodine or shellfish, or history of anaphylactic reaction to any food item.
  • No Recent (last 6 months) episode of acute kidney injury, have sickle cell disease, or have current indwelling nephrostomy tubes.
  • No Edema beyond trace edema, because this will impact iohexol equilibration and distribution.
  • No Ascites (including pleural effusion) beyond trace ascites, because this will impact iohexol equilibration and distribution.
  • No Whole- or part-limb amputees, because this will impact iohexol equilibration and distribution.
  • Ability to maintain a constant dose and schedule of anti-inflammatory agents, diuretics, angiotensin II receptor blockers (ARB) and angiotensin converting enzyme inhibitors (ACEi) for one week prior to study visit, as this impacts renal function. If the patient is on a NSAID, diuretic, ARB or ACEi, they are eligible as long as these agents are taken on a set schedule for 7 or more days prior to study (and not on an "as needed" basis as that can cause fluctuations in renal function).
  • Adequate venous access to obtain PK specimens.

This study is for patients age 18 and older.

Available at: Hartford Hospital

Cancer Clinical Research Office